By a News Reporter-Staff News Editor at Veterinary Week -- A new study on Veterinary Medicine is now available. According to news reporting originating in Basel, Switzerland, by VerticalNews journalists, research stated, “Robenacoxib (Onsior ™) is a non-steroidal anti-inflammatory drug developed for canine and feline use for the control of pain and inflammation. It is available as both tablets and solution for injection.”
The news reporters obtained a quote from the research from Elanco Animal Health, “The objective of this safety study was to investigate the interchangeable use of two robenacoxib formulations in dogs using a novel study design alternating between oral tablets and subcutaneous injections. Thirty-two naive healthy 4-month dogs were enrolled in this 88-day study and were randomized among four groups to be untreated …
CITATION: (2017-12-25), Researchers from Elanco Animal Health Detail New Studies and Findings in the Area of Veterinary Medicine [Safety evaluation of the interchangeable use of robenacoxib (Onsior ™) tablets and solution for injection in dogs], Veterinary Week, 80, ISSN: 1944-2785, BUTTER® ID: 014899711
From the newsletter Veterinary Week.
https://www.newsrx.com/Butter/#!Search:a=14899711
NewsRx® offers 195 weekly newsletters providing comprehensive information on all professional topics, ranging from health, pharma and life science to business, tech, energy, law, and finance. Our newsletters report only the most relevant and authoritative information from qualified sources.